PPD and DiabetesAmerica Enter Exclusive Partnership

Tuesday, December 22, 2009 07:37 AM

Wilmington, N.C.-based PPD has entered into an exclusive partnership with Houston, Texas-based DiabetesAmerica to provide clinical research training and support to the company’s 17 clinical trial centers across Texas and Arizona.

The contract research organization (CRO) will support more than 20 clinical trial investigators conducting type 1 and type 2 diabetes clinical trials. In return, DiabetesAmerica will work exclusively with PPD for a minimum of three years to provide clinical research services for endocrine and metabolic disease development programs. PPD will be able to recruit clinical trial participants from DiabetesAmerica’s 16,000-plus patient database.

"Diabetes is a disease with serious complications that affects more than 23 million Americans," said Mike Wilkinson, executive vice president of clinical development at PPD. "DiabetesAmerica's patient database expands our ability to offer clinical trial options to a broader population of people living with this increasingly common disease."

Share:          
CWWeekly

May 21

Parexel consultant testifies on FDA biosimilars guidance

Global Telecom Testing checks ex-U.S. toll-free phone lines for multinational clinical trials

To read the full articles for this issue of CWWeekly, please click here for subscription information.

Already a digital subscriber? Access this issue now.

CWWeekly

May

Newer sites most optimistic about the future
Investigative sites of all sizes, from part-time physician-run sites to large dedicated research centers, report a rebound in operating conditions, according to a new CenterWatch analysis, yet sites from each subgroup indicate they have concerns…

Risk-based monitoring slow to catch on with industry
It's estimated that the cost of physically sending monitors to all investigative sites at regular intervals, a model the industry itself developed and has adhered to for about a decade, eats up one-third to one-half of…

Eye On Millennium
Millennium, The Takeda Oncology Company, discovers and develops novel treatments applying world-class recombinant technology to a wide variety of oncology disease targets…

To read the full articles for this issue of The CenterWatch Monthly, please click here for subscription information.

Already a digital subscriber? Access this issue now.

JobWatch centerwatch.com/jobwatch

Featured Jobs